Best data room providers for life sciences and biotech

Disclosure in four steps

Biotech partnering, licensing and M&A share a pattern. Any interested party sees a non-confidential summary. Under a confidential disclosure agreement (CDA), a counterparty sees the pipeline and IP overview. Clinical and preclinical data goes to named reviewers, often in a clean team. Regulatory files, manufacturing details and key contracts open only after exclusivity.

Each step is a permission change, not a new room. Build all four layers into the index from day one and move each counterparty up as agreements are signed.

The same deal on a calendar

The four steps rarely happen in four weeks. A licensing or partnering negotiation runs to the rhythm of the partner’s internal reviews, and a data readout can pause it entirely.

Who is on the other side

The counterparty is rarely one team. A large pharma partner may send business development, a clinical team, regulatory specialists, a CMC (chemistry, manufacturing and controls) group, IP counsel and external advisers. Each needs different folders. Give them separate groups, so a scientist reviewing efficacy data cannot open the royalty terms, and the licensing lead does not have to wade through patient-level tables.

Universities and research institutes add another layer. Technology transfer offices often hold rights to early IP and may need to see license terms but not commercial models.

Timing also differs from a company sale. A licensing negotiation may pause for months while a trial reads out, then restart with a new set of reviewers. Rather than closing and reopening the room, suspend the counterparty group and keep the index intact. When talks resume, the audit trail still shows what was seen in the first phase, which helps if a question about prior disclosure ever arises.

Data that needs special handling

In the United States, health information held by covered entities and their business associates falls under the HIPAA Privacy Rule. Most deal rooms should hold de-identified data in any case. If your regulatory files include electronic records kept under 21 CFR Part 11, treat the data room as a place for review copies, not the system of record.

Outside the United States, health data about identifiable people is a special category of personal data under the General Data Protection Regulation in the EU and UK, with stricter conditions for sharing. De-identification before upload is the simplest way to keep such data out of the room altogether.

Risks particular to science deals

Ideas that travel in people’s heads. Scientists who review a counterparty’s data cannot unlearn it. Many agreements address this through residuals clauses or restrictions on reviewers’ later work. Keeping the review group small and named makes those clauses easier to live with.

Inventorship disputes. When two companies work on related science, a later patent can prompt the question of who contributed what. The audit trail, showing which reviewer opened which document on which date, is often the most objective record available.

Early disclosure that affects patents. An unpublished application shown too widely can complicate the patent strategy. View only, watermarking and named users are the minimum for these files.

Long pauses. When talks stop for a readout, access often stays open by default. Suspend the group instead, and reopen it deliberately.

How to choose for a partnering room

The four picks differ in ways that matter to a science deal. In our provider data, Ellty, ShareVault and iDeals offer document rights control and a Q&A module; Box offers neither, which is why it suits collaboration more than negotiation. Built-in redaction comes only with iDeals among the four. ShareVault, iDeals and Box support SSO and hold ISO 27001, which large pharma partners’ security teams often ask about; Ellty relies on SOC 2 Infrastructure and has no SSO, so check the partner’s requirements before shortlisting. Ellty adds built-in AI tools and e-signature, which help when a term sheet and the diligence record should live in the same place.

A practical test: invite one reviewer from each of the partner’s teams into a trial room and ask them to find a specific document. The provider that makes that easy for a scientist, not just for a deal lawyer, will save weeks over a long negotiation.

Planning the budget

Life sciences rooms often stay open longer than corporate deal rooms. Partnering talks can run for many months, and a company may keep a standing room for several counterparties at once. That favors predictable monthly pricing.

Ellty publishes a price from $149/mo with a 14-day free trial. ShareVault and iDeals quote on request; ask how pricing works for a room that stays open for a year or more with several counterparties. Box starts from $15/user/mo, which suits internal collaboration but adds up when many external reviewers need seats. All figures are indicative, confirm with the provider. See VDR pricing for the main models and our methodology for how we score providers.

The estimator below starts from an illustrative nine-month partnering room with about 20 external reviewers and 8,000 pages; extend the duration if several partners will run through the same room in sequence.